Fenofibrate therapy to lower serum triglyceride concentrations in persons with spinal cord injury: A preliminary analysis of its safety profile

Fenofibrate is a medication used to lower high triglyceride levels in the blood. People with spinal cord injuries often have different lipid profiles, and standard treatment guidelines may not apply to them. This study looks at whether fenofibrate is safe for people with spinal cord injuries when used to lower triglyceride levels based on modified intervention thresholds. The study involved 15 participants with spinal cord injuries who took fenofibrate daily for 4 months. Researchers monitored their liver and kidney function, as well as their overall health, to check for any negative side effects. The results suggest that fenofibrate, when used with modified intervention thresholds, does not lead to more adverse events in people with spinal cord injuries compared to the general population, indicating it is generally well-tolerated.

• 1
  Four out of 15 participants experienced an adverse event, including gastrointestinal distress and elevated liver enzymes, leading to three subjects discontinuing the medication.
• 2
  Two participants discontinued treatment after 2 months due to not responding to treatment (less than 25% reduction in serum TG concentration).
• 3
  Ten participants completed the 4-month trial without experiencing an adverse event.